Biogen Agrees To Acquire Reata Pharmaceuticals For $172.50 Per Share In Cash, Reflecting An Enterprise Value Of $7.3B
Portfolio Pulse from Benzinga Newsdesk
Biogen has agreed to acquire Reata Pharmaceuticals for $172.50 per share in cash, reflecting an enterprise value of $7.3 billion.
July 28, 2023 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's acquisition of Reata Pharmaceuticals could potentially strengthen its portfolio and market position.
The acquisition of Reata Pharmaceuticals could potentially add valuable assets to Biogen's portfolio, strengthening its market position and potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Reata Pharmaceuticals is being acquired by Biogen for $172.50 per share in cash, reflecting an enterprise value of $7.3 billion.
The acquisition price of $172.50 per share in cash represents a significant premium to Reata Pharmaceuticals' current market price, which is likely to drive its stock price up in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100